Last reviewed 2026-04-19 · How we verify

Plaque psoriasis

Approved treatments

• Flucorticin
• Cosentyx · Janssen Research & Development, LLC
• Sotyktu · Bristol-Myers Squibb
  Sotyktu works by blocking the TYK2 enzyme, which is involved in the inflammatory response and contributes to the development of psoriasis.
• Aclovate
• Stelara · Biocon Biologics UK Ltd
  Stelara binds to the p40 subunit of IL-12 and IL-23, reducing inflammation in autoimmune diseases.
• tumor necrosis factor inhibitors (TNFi) · Pfizer
• Raptiva · National Institute of Dental and Craniofacial Research (NIDCR)
• Cordran · Aqua Pharms
• Kyntheum · Valeant Luxembourg
  Kyntheum works by blocking the interleukin-17 receptor, a protein that plays a key role in inflammation.
• Daliresp · Arcutis
  Daliresp works by blocking an enzyme called phosphodiesterase 4, which helps reduce inflammation in the body.
• Cutivate · Teva Pharm
• Temovate · Fougera Pharms
• Otezla · Amgen
  Apremilast inhibits PDE4, increasing intracellular cAMP levels, but the exact therapeutic mechanism is unclear.
• Abrilada · AbbVie
  Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors.
• Topicort · Taro
• Derma-Smoothe/Fs · Eurofarma
• Cloderm · Legacy Pharma
• Cortone
• Ultravate · Ranbaxy
  Ultravate works by binding to the glucocorticoid receptor, triggering a cascade of anti-inflammatory effects that reduce skin inflammation.
• Diprolene · Merck & Co.
  Diprolene works by binding to the glucocorticoid receptor in the skin, which reduces inflammation and suppresses the immune system.
• Otezla · L.H. Kircik, M.D.
• Verdeso · Padagis Us
• Betamethasone Valerate · Fougera Pharms Inc
• Decadron · Generic (originally Merck)
• Flonase · GSK (GlaxoSmithKline)
• Dovonex
  Calcipotriene works by binding to the Vitamin D3 receptor, which helps to regulate the growth of skin cells and reduce inflammation.
• Humira · AbbVie
  Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors.
• TNF Inhibitor · Pfizer
• Stelara · Johnson & Johnson
  Ustekinumab binds to the p40 subunit of IL-12 and IL-23, disrupting their signaling and reducing inflammation.
• Cosentyx · Novartis
  Secukinumab selectively binds IL-17A cytokine and inhibits its interaction with IL-17 receptor.
• calcipotriol · NeoStrata Company, Inc.
• Syprine · Bausch Health
• Cimzia · UCB
  Certolizumab pegol binds to and neutralizes human TNFα, reducing inflammation without causing antibody-dependent cell-mediated cytotoxicity.
• Remicade · Johnson & Johnson
  Infliximab binds to TNFα, blocking its interaction with receptors, reducing inflammation and immune responses.
• Remicade · Shanghai Biomabs Pharmaceutical Co., Ltd.
• Tremfya · Johnson & Johnson
  Guselkumab binds to IL-23's p19 subunit, blocking its interaction with the IL-23 receptor and inhibiting proinflammatory cytokine release.
• Remicade · Johnson & Johnson
  Infliximab-dyyb neutralizes TNFα by binding with high affinity to soluble and transmembrane forms, inhibiting receptor binding.
• CYLTEZO · BOEHRINGER INGELHEIM
• ILUMYA · SUN PHARMA GLOBAL
• IXIFI · PFIZER INC
• Taltz · Yale University
• BIMZELX · UCB INC
• Nasonex · University of Alberta
• Medrol · Generic (originally Upjohn/Pfizer)
  Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions.
• Betamethasone 17-Benzoate
• Cortef · Generic (originally Merck/Upjohn)
• TACALCITOL
  TACALCITOL works by binding to the Vitamin D3 receptor, which helps to reduce inflammation and modulate the immune response.
• Rodinolone
• Flixotide · Mundipharma Research Limited
• Fluticason · Creighton University

Pipeline

• PF-07038124 · Pfizer Inc. — Phase 2

Clinical guidelines

• FDA label — 1L|2L
  Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
• FDA label — 2L
  treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.
• FDA label — 1L
  TALTZ is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
• FDA label — 1L
  Enbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.
• FDA label — 1L
  Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy.
• FDA label — 1L
  Secukinumab is indicated for the treatment of moderate to severe hidradenitis suppurativa in adults and pediatric patients 12 years of age and older.

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Plaque psoriasis patent landscape — cliff calendar, originator estates, attackable patents
• Plaque psoriasis treatment landscape brief
• Plaque psoriasis treatment updates RSS

Frequently asked questions about Plaque psoriasis

Related

• Treatment landscape: Plaque psoriasis patent cliff · Plaque psoriasis CI report
• Treatment: Flucorticin
• Treatment: Cosentyx · Janssen Research & Development, LLC
• Treatment: Sotyktu · Bristol-Myers Squibb
• Treatment: Aclovate
• Treatment: Stelara · Biocon Biologics UK Ltd
• All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing